Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
MolMed Pulls Zalmoxis Cell Therapy In EU
Company Withdraws Marketing Authorization After Failed Trial Results
Oct 11 2019
•
By
Vibha Sharma
Zalmoxis Failed To Meet Its Primary Endpoint • Source: Shutterstock
More from Clinical Trials
More from R&D